ALK (L1196M/G1202R)
Sign in to save this workspaceALK · Variant type: compound · HGVS: p.L1196M;p.G1202R
Components
p.L1196Mp.G1202R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Repotrectinib | 98.6% | 1.4% | 84.21 |
| 2 | Gilteritinib | 90.0% | 10.0% | 88.97 |
| 3 | Defactinib | 51.4% | 48.6% | 92.68 |
| 4 | Entrectinib | 50.4% | 49.6% | 93.69 |
| 5 | Mobocertinib | 23.5% | 76.5% | 97.22 |
| 6 | Sunitinib | 19.3% | 80.7% | 91.73 |
| 7 | Upadacitinib | 18.7% | 81.3% | 97.98 |
| 8 | Selumetinib | 14.9% | 85.1% | 100.00 |
| 9 | Neratinib | 13.6% | 86.4% | 93.18 |
| 10 | Fedratinib | 12.4% | 87.6% | 96.21 |
| 11 | Umbralisib | 10.6% | 89.4% | 98.74 |
| 12 | Abrocitinib | 9.0% | 91.0% | 99.50 |
| 13 | Darovasertib | 7.7% | 92.3% | 96.99 |
| 14 | Pralsetinib | 7.1% | 92.9% | 93.43 |
| 15 | Tucatinib | 4.5% | 95.5% | 99.75 |
| 16 | Apatinib | 3.4% | 96.6% | 97.73 |
| 17 | Tenalisib | 3.1% | 96.9% | 97.98 |
| 18 | Selpercatinib | 3.0% | 97.0% | 96.72 |
| 19 | Tivozanib | 2.7% | 97.3% | 92.42 |
| 20 | Pemigatinib | 2.7% | 97.3% | 98.23 |
| 21 | Ripretinib | 2.5% | 97.5% | 92.95 |
| 22 | Pacritinib | 2.3% | 97.7% | 88.64 |
| 23 | Infigratinib | 2.2% | 97.8% | 98.24 |
| 24 | Palbociclib | 2.1% | 97.9% | 98.75 |
| 25 | Leniolisib | 1.7% | 98.3% | 100.00 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Repotrectinib | 98.6% | 99.4% | -0.8% |
| Gilteritinib | 90.0% | 99.5% | -9.5% |
| Defactinib | 51.4% | — | — |
| Entrectinib | 50.4% | 98.8% | -48.4% |
| Mobocertinib | 23.5% | — | — |
| Sunitinib | 19.3% | 87.7% | -68.4% |
| Upadacitinib | 18.7% | — | — |
| Selumetinib | 14.9% | — | — |
| Neratinib | 13.6% | — | — |
| Fedratinib | 12.4% | — | — |
| Umbralisib | 10.6% | — | — |
| Abrocitinib | 9.0% | — | — |
| Darovasertib | 7.7% | — | — |
| Pralsetinib | 7.1% | 82.6% | -75.4% |
| Tucatinib | 4.5% | — | — |
| Apatinib | 3.4% | — | — |
| Tenalisib | 3.1% | 45.2% | -42.1% |
| Selpercatinib | 3.0% | — | — |
| Tivozanib | 2.7% | — | — |
| Pemigatinib | 2.7% | — | — |
| Ripretinib | 2.5% | — | — |
| Pacritinib | 2.3% | 55.3% | -53.0% |
| Infigratinib | 2.2% | — | — |
| Palbociclib | 2.1% | — | — |
| Leniolisib | 1.7% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 21.1ms